Drugs News and Research

RSS

Henry Ford researchers propose new treatment strategy for stroke, other neurological disorders

Medicine should reconsider how it treats stroke and other neurological disorders, focusing on the intrinsic abilities of the brain and nervous system to heal themselves rather than the "modest" benefits of clot-busting drugs and other neuroprotective treatments.

3 Mar 2015

Alizé Pharma announces launch of AZP-531 Phase II trial in patients with Prader-Willi syndrome

Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today announces the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome.

3 Mar 2015

New study examines risk factors for use of synthetic marijuana among teens

Synthetic cannabinoids ("synthetic marijuana"), with names like Spice, K2, Scooby Doo and hundreds of others, are often sold as a "legal" alternative to marijuana. Often perceived as a safe legal alternative to illicit drug use, synthetic marijuana use was associated with 11,561 reports of poisonings in the United States between January 2009 and April 2012.

3 Mar 2015

Anticholinergic medications associated with pneumonia risk in older people

Taking commonly used medications with anticholinergic effects is associated with a significantly higher risk for developing pneumonia in a study of more than 3,000 older Group Health patients living in the community--not in nursing homes.

3 Mar 2015

People with diabetes more prone to depression, anxiety

People with diabetes are more prone to anxiety and depression than those with other chronic diseases that require similar levels of management. The reasons for this aren't well understood, but Joslin Diabetes Center researchers have discovered one potential explanation.

2 Mar 2015

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that it has licensed a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen.

2 Mar 2015

Study shows importance of disclosing physician conflicts of interest in MS ISCTs to potential participants

If you're one of the nearly half a million Americans living with multiple sclerosis (MS) - a slowly disabling disease of the central nervous system - you are likely dependent on disease-modifying drugs to prevent symptoms such as vision problems, balance issues and weakness. Often, these treatments have been developed through pharmaceutical industry-sponsored clinical trials (ISCT) in collaboration with academic or private practice physicians who care for MS patients.

2 Mar 2015

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of cancer of the fallopian tube.

2 Mar 2015

Bielefeld University chemists develop copper molecule that could help prevent spread of cancer

Chemists at Bielefeld University have developed a molecule containing copper that binds specifically with DNA and prevents the spread of cancer. First results show that it kills the cancer cells more quickly than cisplatin - a widely used anti-cancer drug that is frequently administered in chemotherapy.

2 Mar 2015

U-M researchers reveal key role of two enzymes that help the body to remove cholesterol, other lipids

With the aid of X-ray crystallography, researchers at the University of Michigan have revealed the structures of two closely related enzymes that play essential roles in the body's ability to metabolize excess lipids, including cholesterol.

2 Mar 2015

Study explores use of antipsychotic medications among pediatric patients

More kids nationwide are taking medications designed to treat such mental illnesses as schizophrenia and bipolar disorder, and pediatricians and psychiatrists at the University of Vermont want to know why.

2 Mar 2015

Study debunks false reports surrounding risk of hormone therapy

For over a decade, hormone therapy (HT) has been a hot topic in medicine. Unfortunately, women are still confused and concerned about using HT after two federally-funded studies linked HT to potentially serious health risks.

2 Mar 2015

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets.

1 Mar 2015

Physicians urge households to add 'clean my medicine cabinet' to Spring cleaning chores list

After marijuana and alcohol, the most commonly abused drugs by those over the age of 14 are prescription and over-the-counter medications.

28 Feb 2015

Pharmacyclics completes toxicology studies of BTK inhibitor in RA

Pharmacyclics, Inc. today announced that longer-term toxicology studies for its newly developed Bruton's tyrosine kinase (BTK) inhibitor for rheumatoid arthritis, or RA, have been completed.

28 Feb 2015

WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, congratulates our partner TaiMed Biologics for receiving breakthrough therapy designation from the U.S. FDA for ibalizumab (TMB355).

28 Feb 2015

CLL patients discontinue ibrutinib drug due to disease progression during clinical trials

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study published online in JAMA Oncology.

28 Feb 2015

Researchers investigate efficiency of drug research and development

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could be responsible.

28 Feb 2015

Novel financing technique may unlock funding for developing 'orphan' drugs to treat rare diseases

A paper published today, "Financing translation: Analysis of the NCATS rare-diseases portfolio" in Science Translational Medicine, demonstrates the potential of a new financing technique to reduce the risk associated with investing in the treatment of new diseases and potentially unlock new levels of funding for developing so-called "orphan" drugs.

28 Feb 2015

Rare Disease Day 2015 raises awareness of challenges faced by rare cancer patients

Within the "umbrella" of rare diseases, rare cancer patients confront particular problems. Most rare diseases have an identified genetic origin. In contrast, rare cancers are mainly acquired diseases.

28 Feb 2015

Drugs News and Research

Henry Ford researchers propose new treatment strategy for stroke, other neurological disorders

Alizé Pharma announces launch of AZP-531 Phase II trial in patients with Prader-Willi syndrome

New study examines risk factors for use of synthetic marijuana among teens

Anticholinergic medications associated with pneumonia risk in older people

People with diabetes more prone to depression, anxiety

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Study shows importance of disclosing physician conflicts of interest in MS ISCTs to potential participants

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Bielefeld University chemists develop copper molecule that could help prevent spread of cancer

U-M researchers reveal key role of two enzymes that help the body to remove cholesterol, other lipids

Study explores use of antipsychotic medications among pediatric patients

Study debunks false reports surrounding risk of hormone therapy

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Physicians urge households to add 'clean my medicine cabinet' to Spring cleaning chores list

Pharmacyclics completes toxicology studies of BTK inhibitor in RA

WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

CLL patients discontinue ibrutinib drug due to disease progression during clinical trials

Researchers investigate efficiency of drug research and development

Novel financing technique may unlock funding for developing 'orphan' drugs to treat rare diseases

Rare Disease Day 2015 raises awareness of challenges faced by rare cancer patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News